Avidity Biosciences to Acquire Recursion Pharmaceuticals for $1.5B
| Field | Detail |
|---|---|
| Company | Avidity Biosciences, Inc. |
| Form Type | 8-K |
| Filed Date | Jul 23, 2025 |
| Risk Level | medium |
| Sentiment | mixed |
Sentiment: mixed
Topics: acquisition, merger, biotech, ai-drug-discovery
TL;DR
Avidity is buying Recursion for $1.5B in cash & stock, closing Q4 2025.
AI Summary
Avidity Biosciences, Inc. announced on July 23, 2025, that it has entered into a definitive agreement to acquire all outstanding shares of Recursion Pharmaceuticals, Inc. The transaction is valued at approximately $1.5 billion, consisting of cash and stock. This acquisition is expected to close in the fourth quarter of 2025, subject to customary closing conditions and regulatory approvals.
Why It Matters
This significant acquisition could reshape the landscape of drug discovery and development by combining Avidity's RNA therapeutics with Recursion's AI-driven platform, potentially accelerating the creation of new medicines.
Risk Assessment
Risk Level: medium — The acquisition involves a substantial financial commitment and integration risks, with success dependent on regulatory approvals and achieving projected synergies.
Key Numbers
- $1.5B — Acquisition Value (Total consideration for Recursion Pharmaceuticals)
- Q4 2025 — Expected Closing (Target timeframe for the acquisition to be finalized)
Key Players & Entities
- Avidity Biosciences, Inc. (company) — Acquiring company
- Recursion Pharmaceuticals, Inc. (company) — Target company
- $1.5 billion (dollar_amount) — Acquisition valuation
- July 23, 2025 (date) — Announcement date
- fourth quarter of 2025 (date) — Expected closing period
FAQ
What is the total value of the proposed acquisition?
The definitive agreement values the acquisition of Recursion Pharmaceuticals at approximately $1.5 billion.
When is the acquisition expected to close?
The transaction is anticipated to close in the fourth quarter of 2025.
What is the nature of the agreement between Avidity Biosciences and Recursion Pharmaceuticals?
Avidity Biosciences, Inc. has entered into a definitive agreement to acquire all outstanding shares of Recursion Pharmaceuticals, Inc.
What are the primary components of the acquisition consideration?
The acquisition is valued at approximately $1.5 billion, consisting of a combination of cash and stock.
What conditions must be met for the acquisition to be completed?
The acquisition is subject to customary closing conditions and regulatory approvals.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 23, 2025 regarding Avidity Biosciences, Inc..